WO2004082718A1 - 難水溶性抗癌剤と新規ブロック共重合体を含むミセル調製物 - Google Patents
難水溶性抗癌剤と新規ブロック共重合体を含むミセル調製物 Download PDFInfo
- Publication number
- WO2004082718A1 WO2004082718A1 PCT/JP2004/003647 JP2004003647W WO2004082718A1 WO 2004082718 A1 WO2004082718 A1 WO 2004082718A1 JP 2004003647 W JP2004003647 W JP 2004003647W WO 2004082718 A1 WO2004082718 A1 WO 2004082718A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- anticancer agent
- block copolymer
- micelle preparation
- general formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a micelle preparation formed from a novel block copolymer and a poorly water-soluble anticancer agent, an anticancer agent containing the same as an active ingredient, and the block copolymer.
- solubilization of poorly water-soluble anticancer agents is an important technique for producing pharmaceutical preparations for intravenous administration, particularly for oral or parenteral preparations.
- One method of solubilizing poorly water-soluble anticancer agents is to add a surfactant.
- a surfactant for example, polyoxyethylene castor oil derivative (Cremohol) is used to solubilize PYX. Is the way.
- a method for solubilizing a poorly water-soluble anticancer agent a method in which a block copolymer that forms micelles is used as a drug carrier is disclosed in, for example, Patent Document 1, Patent Document 2, and Patent Document 3
- Patent Document 4 describes a non-crystalline resin using a poly (ethylene oxide) monopoly (? Benzyl spartate monocosanolate) acid copolymer. It describes the taxel-filled micelles.
- Patent Document 1 Japanese Patent Application Laid-Open No. 6_10 7 5 6 5
- Patent Document 2 Japanese Patent Application Laid-Open No. 6-2 0 6 8 1 5
- Patent Document 3 Japanese Patent Laid-Open No. 11-3 3 5 2 6 7
- Patent Document 4 Japanese Patent Application Laid-Open No. 2000-0 1-2 2 6 2 94 Issue to be Solved by the Invention
- the surfactant solubilization method has harmful side effects such as hypersensitivity reaction caused by it, and the stability of the preparation is low, so the solution is stored or left for a long time. Then, there is a problem that the drug precipitates.
- poorly water-soluble anticancer agents such as When a pharmaceutical preparation using a mouth copolymer as a drug carrier is administered intravenously, it maintains a higher drug blood concentration than single administration, and enhances its pharmacological effects and reduces drug side effects. Mitigation has not been achieved.
- the present inventors have found a micelle preparation comprising a novel block copolymer and a poorly water-soluble anticancer agent, thereby completing the present invention.
- R1 (OCH 2 CH 2) n -0-R2- (NHCOCH) m x -. (NHCO-R3-CH) x - NHR4
- R 1 represents a hydrogen atom or a (C 1 to C 5) alkyl group
- R 2 represents a (C 1 to C 5) alkylene group
- R 3 represents a methyl group.
- R 4 represents a hydrogen atom or a (C 1 to C 4) acyl group
- R 5 represents a hydroxyl group or an aryl group that may have a substituent ( C 2 to C 8) represents an alkoxyl group or a substituted (C 1 to C 4) alkylamino group, or an amino group having an amino acid or peptide derivative as a residue.
- N is 5-1 0 0
- 111 is 2-3 0
- x is an integer from 1 to 3 0 0, where the proportion of hydroxyl group in R 5 is 0 to 9 9%
- X is m No greater than m
- R 1 is a methyl group
- R 2 is a trimethylene group
- R 3 is a methylene group
- R 4 is a acetyl group
- R 5 is an unsubstituted phenyl.
- An anticancer agent comprising the micelle preparation according to any one of 1) to 5) as an active ingredient;
- R 1 represents a hydrogen atom or a (C 1 to C 5) alkyl group
- R 2 represents a (C 1 to C 5) alkylene group
- R 3 represents a methylene group or an ethylene group
- R 4 represents a hydrogen atom or a (C 1 to C 4) acyl group
- R 5 represents an aryl group (C 2 to C 8) which may have a hydroxyl group or a substituent.
- Block copolymer represented by: 8) In general formula (1), R 1 is a methyl group, R 2 is a trimethylene group, R 3 is a methylene group, R 4 is a acetyl group, R 5 is an unsubstituted phenyl (C 3 ⁇ C 6) Alkoxyl group, n is 2 0 — 5 0 0, m is 1 0 — 1 0 0, X is 1 — 1 0 0, but X is not greater than m The above-mentioned 7) block copolymer.
- the micelle preparation of the present invention has the above general formula (1) [wherein R 1 represents a hydrogen atom or a (C 1 -C 5) alkyl group, and R 2 represents (C 1 -C 5) alkylene].
- R 3 represents a methylene group or an ethylene group
- R 4 represents a hydrogen atom or a (C 1 -C 4) acyl group
- R 5 represents a hydroxyl group or a substituent.
- n represents an integer of 5 — 1 0 0
- m represents an integer of 2 — 3 0
- X represents an integer of 1 — 3 0 0, provided that the hydroxyl group in R 5
- the ratio is 0 to 99%, and X is not greater than m] It is formed from the block copolymer represented by these, and a poorly water-soluble anticancer agent.
- examples of R 1 include a hydrogen atom or a (C 1 -C 5) alkyl group, and (C 1 -C 5) Alkyl groups are preferred.
- Specific examples of (C 1 -C 5) alkyl groups include methyl, ethyl, n-propyl, i-propyl, II-butyl, s-butyl, and t-butyl.
- Group, n-pentyl group and the like are mentioned, and methyl group is particularly preferable.
- (C 1 to C 5) alkylene group of R 2 include a methylene group, an ethylene group, a trimethylene group, and a tetramethylene group. Ethylene groups and trimethylene groups are preferred.
- R 3 includes a methylene group or an ethylene group, and a methylene group is preferred.
- R 4 may be a hydrogen atom or a (C 1 -C 4) acyl group, preferably a (C 1 -C 4) acyl group, specifically a formyl group, an acetyl group, a propionyl group. Group, pentyl group and the like, and acetyl group is particularly preferable.
- R 5 is an aryl (C 2 -C 8) alkoxyl group which may have a hydroxyl group or a substituent, or a (C 1 -C 4) alkylamino group having a substituent, Alternatively, it is an amino group having an amino acid or peptide derivative as a residue, and may be the same or different in one molecule.
- the proportion of R 5 being a hydroxyl group is 0% to 99%, preferably 0% to 90%, particularly preferably 15% to 85%, and most preferably 35% ⁇ 80%.
- the aryl (C 2 -C 8) alkoxyl group is a linear or branched (C 2 -C 8) alkoxyl group to which an aromatic hydrocarbon group such as a phenyl group or a naphthyl group is bonded.
- phenethyloxy group phenylpropoxy group, phenylpropyloxy group, phenylpentyloxy group, phenylhexyloxy group, phenylheptyloxy group, phenyloctyloxy group, naphthylethyl
- phenethyloxy group phenylpropoxy group, phenylpropyloxy group, phenylpentyloxy group, phenylhexyloxy group, phenylheptyloxy group, phenyloctyloxy group, naphthylethyl
- naphthylethyl examples thereof include a toxi group, a naphthylpropoxy group, a naphthyloxy group, and a naphthylpentyloxy group.
- the aryl (C 2 to C 8) which may have a substituent may be substituted with a methoxy group, an ethoxy group, an iso-propoxy group, an n-butoxy group.
- Lower alkyloxy groups such as xoxy group, t-butoxy group, halogens such as fluorine atom, chlorine atom, bromine atom Atoms, nitro groups, cyan groups and the like can be mentioned.
- Substituents in which the number of substitutions of the substituent is 1 to the maximum number that can be substituted, and all substitutable positions are included in the present invention, but unsubstituted is preferred.
- An optionally substituted aryl (C2-C8) alkoxyl group is preferably an unsubstituted phenyl (C3-C6) alkoxyl group, for example, unsubstituted.
- examples thereof include a phenylpropoxy group, an unsubstituted phenylbutoxy group, an unsubstituted phenylpentyloxy group, and an unsubstituted phenylhexyloxy group.
- Particularly preferred is an unsubstituted phenylbutoxy group.
- R 5 in the block copolymer represented by the general formula (1) used in the micelle preparation of the present invention examples include aryl (C1-C4) alkylamino groups which may have a substituent.
- the aryl (C 1 -C 4) alkylamino group includes a linear or branched (C 1 -C 4) alkyl group to which an aromatic hydrocarbon group such as a phenyl group or a naphthyl group is bonded.
- benzylamino group phenethylamino group, phenylpropylamino group, phenylbutylamino group, naphthylmethylamino group, naphthylethylamino group, naphthyl group.
- Butyramino Groups and the like include benzylamino group, phenethylamino group, phenylpropylamino group, phenylbutylamino group, naphthylmethylamino group, naphthylethylamino group, naphthyl group. Butyramino Groups and the like.
- Optional aryl (C1-C4) substituents on the alkylamino group include a methoxy group, an ethoxy group, an isopropoxy group, and an n-butoxy group. , T-butoxy group and the like lower alkoxyl groups, fluorine atom, chlorine atom, bromine atom and other halogen atoms, nitro group, and cyano group. Substituents having 1 to the maximum number of substitutable substituents and all substitutable substituents are included in the present invention. However, an unsubstituted aryl (C 1 to C 4) alkylamino is included in the present invention. Group is preferred.
- aryl (C1-C4) alkylamino group which may have a substituent include an unsubstituted pendylamino group and an unsubstituted phenylethylamino group. That's right.
- R 5 represented by the general formula (1) may be an amino group having an amino acid or peptide derivative as a residue.
- Such amino groups are ⁇ - or /? Primary amino acids or primary amino acids that constitute derivatives of peptides in which two or more amino acids are linked by an amine bond. It is a minor group.
- Examples of amino acid or peptide derivatives include esterified main chain carboxylic acids, esterified side chain carboxylic acids, etherified side chain hydroxyl groups, and the like. Specifically, for example, Asanolic acid dibenzyl ester, ⁇ -alanyl-serine benzyl ether benzyl ester (? -Valanyl-0-pentyl-1-L-serine benzyl ester) and the like.
- n is 5 to 100, preferably 2 0 to 500, particularly preferably.
- An integer of 8 0 — 4 0 0, m is 2 — 3 0 0, preferably 1 0 — 1 0 0, particularly preferably 1 5 — an integer of 0, X is 1 — 3 0 0, preferably 1 — 1 0 0, particularly preferably 1-60, but X is not greater than m.
- R 5 described in Patent Document 3 and Patent Document 4 may have a substituent.
- Examples include a method of partially hydrolyzing a compound having a reel (C2-C8) alkoxyl group or a substituted (C1-C4) alkylamino group with an acid or alkali. .
- a compound having a group other than a hydroxyl group at R 5 is a compound of the general formula (1) in which all of R 5 are hydroxyl groups.
- an aryl (C 2 to C 8) alcohol which may have a substituent, and a substituent (C 1 ⁇ C4) It can also be obtained by dehydration condensation reaction with alkylamines or amino acids or peptide derivatives.
- the aryl (C2-C8) alcohol which may have a substituent is the aryl (C2-C8) alkoxyl group which may have the above-mentioned substituent.
- the (C 1 -C 4) alkylamine having a substituent is an amine corresponding to the (C 1 -C 4) alkylamino group having the above substituent.
- the optionally substituted aryl (C 2 to C 8) alcohol, the substituted (C;! To C 4) alkylamine, amino acid and peptide derivatives are:
- a commercially available compound may be used, or a compound prepared by known organic synthesis or a compound prepared by combining known organic reactions may be used.
- the method for producing a compound in which all of R 5 are hydroxyl groups is not particularly limited, but for example, the method described in Patent Document 2 can be used.
- Examples of the dehydrating condensing agent used in the above dehydrating condensation reaction include force rubodiimide type dehydrating condensing agent.
- 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide is used.
- ED C 1-ethyl-3 ((3-dimethylamino pill)
- EDC ⁇ HC 1 carbodiimide hydrochloride
- DCC dicyclohexylcarbodiimide
- DIPCI diisopropylcarbodiimide
- the dehydrating condensing agent may have a substituent (C 2 to C 8) 0.1 to 20 moles compared to an alcohol or a substituted (C 1 to C 4) alkylamine. It is preferable to use 1 to 5 times the mole.
- hydroxysuccinimide (H 0 S u) 1-hydroxy benzotriazol (HOB t)
- N-hydroxyloxy 5-norbornene 1,2-dicarboxylic acid Imido ⁇ ⁇ ⁇
- diisopropylethylamine etc.
- C2-C8 Alcohol or substituent It may be present in an amount of 0.1 to 20 times, preferably 0.1 to 10 times the mol of the (C 1 to C 4) alkylamine.
- R 5 is a hydroxyl group 0.1 to 5 equivalents are used per 1 equivalent of the carboxyl group of the compound of general formula (1). Is good.
- the dehydration condensation reaction is preferably performed in a solvent.
- the solvent include N, N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), dioxane, and tetrahydrofuran.
- Various materials such as water, water and mixed solvents thereof can be used and are not particularly limited.
- the amount of solvent used is not particularly limited, but it is usually 1 to 500 times by weight with respect to the raw material copolymer.
- the dehydration condensation reaction is preferably performed at ⁇ 10 to 60 ° C., and the reaction may be performed for 2 to 48 hours.
- salts also included in the present invention include alkali metal salts, alkaline earth metal salts, ammonium salts, organic ammonium salts, and the like. Examples thereof include a lithium salt, a calcium salt, an ammonium salt, and a triethylammonium salt.
- the poorly water-soluble anticancer agent in the micelle preparation of the present invention itself does not substantially dissolve in an equal amount of water under the ambient environment such as room temperature or normal pressure, or the same amount of water.
- Preferred for solvent systems with chloroform thus, it means an anticancer drug that can be distributed to the closed-form phase.
- anticancer agents include anthracycline anticancer agents such as adriamycin, taxane anticancer agents such as nocritaxel and docetaxel, and vin-strength lipids such as vincristine.
- Anticancer agents, mesotrexates, derivatives thereof, and the like can be mentioned, and in particular, xanthan anticancer agents, and in particular, paclitaxel.
- the block copolymer and the sparingly water-soluble anticancer agent contained in the micelle preparation of the present invention have a weight ratio of 100:;! To 1: 1, and preferably 100. : 1 to 1.5: 1 and 20: 1 to 2: 1 is particularly preferable. However, if the micelle preparation is water-soluble, as much of the drug may be contained as possible.
- the micelle preparation of the present invention is prepared, for example, by the following method.
- Method b solvent evaporation method Mix a water-immiscible organic solvent solution of a poorly water-soluble anticancer agent in the block copolymer dispersion aqueous solution, and evaporate the organic solvent with stirring.
- the resulting solution is dialyzed in a buffer solution and / or water using a dialysis membrane.
- the poorly water-soluble anticancer agent and the block copolymer are dissolved in a water-immiscible organic solvent, and the resulting solution is mixed with water and stirred to form an oil-in-water (0 / W) emulsion. Strip the organic solvent.
- Patent Document 3 or Patent Document 4 describes the b method and the d method that volatilize the organic solvent.
- the water-immiscible organic solvent is substantially freely mixed with water used for forming polymer micelles in Patent Document 3, for example. It means a solvent with a concept opposite to dimethylformamide (DMF), dimethylsulfoxide (DMS 0), acetonitrile, etc. Examples thereof include chloroform, methyl chloride, toluene, xylene, and n-hexane, or a mixed solvent thereof.
- DMF dimethylformamide
- DMS 0 dimethylsulfoxide
- acetonitrile etc.
- Examples thereof include chloroform, methyl chloride, toluene, xylene, and n-hexane, or a mixed solvent thereof.
- Water-immiscible organic solvent and aqueous medium ie water (including pure water or ion-exchanged water) or isotonicity including saccharides, stabilizers, salt or buffer, etc. Or mix with buffered aqueous solution. At this time, it may contain a small amount of a water-miscible organic solvent or other inorganic salt (for example, sodium sulfate) as long as it does not adversely affect the formation of 0 / W type emulsion. .
- a water-miscible organic solvent or other inorganic salt for example, sodium sulfate
- the water-immiscible organic solvent and the aqueous medium have a volume ratio of 1: 1.
- the mixing means means commonly used for preparing various emulsions, mechanical stirrers, shakers, ultrasonic irradiators and the like can be used.
- the operating temperature at this time is not limited, but it is preferable to set the temperature within the range of about 15 ° C to about 40 ° C in consideration of the temperature stability of the drug, the boiling point of the solvent, and the like.
- micellar preparation aqueous solution can be used as is or the micelle preparation can be used. If there is a possibility that they are agglomerated, the insoluble matter and the precipitate may be filtered after sonication.
- the filtration membrane There is no limitation on the filtration membrane to be used, but a membrane having a pore size of 0.1 to 1 ⁇ m is preferable.
- the micelle preparation of the present invention is stable in an aqueous medium, and the micelle preparation of the present invention increases the drug concentration of a poorly water-soluble anticancer agent in water as compared with the case where no additive is used. be able to. Furthermore, in order to increase the concentration of the drug-containing micelle preparation, it is possible to perform concentration by evacuation or ultrafiltration, freeze drying, or the like.
- the drug concentration per total weight of the drug and the procopolymer is 0.1 to 50% by weight, preferably 1 to 40% by weight, particularly preferably. Therefore, the drug amount is about 0.01 mg or more, preferably about 1 mg or more, particularly preferably 1 ml of the aqueous solution of the micelle preparation. Can be about 2 mg or more.
- the micelle preparation of the present invention becomes a core-shell type micelle having a polyethylene glycol structure portion outside in an aqueous medium, and a poorly water-soluble anticancer agent is added to the hydrophobic portion inside the micelle. It may be included.
- the particle size is measured using a commercially available light scattering particle size analyzer (for example, Otsuka Electronics Co., Ltd., DLS — 7 0 0 ODH type) and the average particle size is 10 to 20 O nm, preferably 20 to 10 O nm.
- An anticancer agent containing the above anticancer agent-containing micelle preparation as an active ingredient is also included in the present invention.
- the dosage is determined by the patient's age, body weight, symptoms, and therapeutic purpose, but the therapeutically effective amount is approximately 50-500 mg. / B ody Z day.
- the pharmaceutical preparation to be administered is not particularly limited as long as the micelle preparation of the present invention is dissolved in a pharmaceutically acceptable solvent, and includes a pharmacologically acceptable additive. Also good.
- the micelle preparation of the present invention also includes lyophilized products.
- the present invention also includes a block copolymer used in the above micelle preparation.
- Example 1 a block copolymer used in the above micelle preparation.
- Enool is E t 0 H
- diisopropylene is IPE
- 4-dimethylaminopyridine is DMAP
- N-hydroxysuccinimide is H 0 Su
- HPLC high Performance liquid chromatogram The first is abbreviated as HPLC.
- PEG produced by the method described in Patent Document 2 average molecular weight 1 2 00 0 0)-p A sp (average polymerization number 3 5) —
- a c (— R 1 in general formula (1) is a methyl group
- R 2 is a trimethylene group
- R 3 is a methylene group
- R 4 is a acetyl group
- R 5 is a hydroxyl group
- n is about 2 7 2
- m is about 35
- X is about 26, (Hereinafter abbreviated as PEG—p A sp —A c)
- This block copolymer 6 (25.2 mg) was dissolved in 2 mL of acetonitrile and then 2 mL of 0.5 N aqueous sodium hydroxide solution was added. Stir at room temperature for 20 minutes. After neutralization with 0.5 mL of acetic acid, the volume was adjusted to 5 mL, and the released 4-phenyl 1-propanol was quantified by HPLC. As a result of analysis, the ester-bonded 4-phenyl-1-hydroxy ester was 44% of poly-norragnoic acid.
- Example 1 PEG — p A sp — A c 200 mg was used, and 4 1-phenyl 1 of Example 1 was converted to 6-phenyl 1 1-hexanol (80.1j). As a result, 2 3 3 mg of block copolymer 10 was obtained in the same manner as in Example 1. As a result of the analysis after the hydrolysis operation in the same manner as in Example 1, the ester-bonded 6-phenyl-1-hexanol was 48% with respect to polyaspartic acid.
- the amount of benzylamine remaining in the reaction solution was quantified with HPLC and calculated based on the result. As a result, the amount of benzylamine bonded with an amine was 61% with respect to the boron aspartic acid.
- Example 6 The pentylamine of Example 6 was converted to L-aspartic acid dibenzyl ester toluenesulfonate (7 1 5 mg) and diisopropylethylamine (2 5 7 ⁇ L) to produce PEG— p A sp — A c 3 Using 0.09 g, 3.35 g of block copolymer 15 was obtained in the same manner as in Example 6. By hydrolyzing under the same conditions as in Example 1, the released benzyl alcohol was quantified and analyzed, and L-aspartic acid dibenzyl ester bonded to block copolymer 15 was It was 23% with respect to polyaspartic acid.
- the benzilamine of Example 6 can be prepared by a general dipeptidic synthesis method./?-alanyl mono-O-benzyl mono-L-serine benzyl ester hydrochloride (3 2 1 mg) and diiso Using PEG-pAsp-Ac (1.51 g) as propyrethylamine (1 4 2 i L), the copolymer 1 6 was prepared in the same manner as in Example 6. 4 9 g was obtained.
- the concentration of pachissen xel was 2.8 mg noml.
- the average particle size was 86.6 nm by a dynamic light scattering photometer (Otsuka Electronics Co., Ltd., DLS — 700 ODH type).
- a Parky micelle micelle preparation was produced. The results are shown in Table 1.
- the obtained block copolymer (10 g) was dissolved in acetonitrile (100 mL), 0.5N aqueous sodium hydroxide solution (22.72 mL) was added, and room temperature was increased. The hydrolysis reaction was carried out for 10 minutes. Stop the reaction by adding 3.79 ml of 6 N hydrochloric acid, transfer to a dialysis membrane (S pectra / P or 7 MWC 03, 500), and dialyze with 3.3 L of ion exchange water for 9 hours or more. (Ion exchange water was changed at least three times). After dialysis, filter with No. 5 B filter paper (Kiriyama Mfg. Co., Ltd., 4 m), freeze-dry, and approximately 50% hydrolyzed poly (ethylene). About 9 g of block copolymer was obtained (polyoxide) (polybenzyl spartate toco succinate).
- the average particle size was 10 7 nm.
- Macrogol 400 00 was added and dissolved to a concentration of 2 O mg / mL, and after sterilization filtration, freeze-dried to obtain a micelle preparation of a comparative example.
- Test Example 1 Invivo anti-tumor effect against Colo 2 2 6 Mouse colon cancer Co 1 on 2 6 cells were implanted subcutaneously on the dorsal side of female CDF 1 mice, and when tumor volume reached around 100 mm 3
- the micelle preparation 10 of the present invention the micelle preparation according to the comparative example, or the paclitaxel was administered from the mouse tail vein for 5 consecutive days, The effect on advanced cancer was examined.
- Each drug was used as it was or diluted with saline in use.
- the drug concentration was set to the Pachi-ri xelel conversion concentration.
- the antitumor effect of the drug was determined by the percentage (T / C%) of the average tumor volume of the administration group to the average tumor volume of the non-administration group on the first day after administration. The results are shown in Table 2.
- miceelle preparation 1 0 3 0 1 3.4 Comparison micelle preparation 3 0 4 2 • 2
- Test Example 2 Transition of concentration of paclitaxel in rat plasma Micellar preparation 10 of Example 9 was diluted with physiological saline, and an aqueous solution of 2.5 mg / mL of paclitaxel equivalent concentration was obtained. did. After dissolving Pakuryu-Xel alone in ethanol, add the same amount of Cremohol (Sigma) as that of Yen-no-ru so that the concentration of Paclitaxel will be 25 mg / mL. And diluted with physiological saline just before administration to 2.5 mg / mL.
- micellar preparation 10 equivalent to paclitaxel 5 mg / kg or single agent of paclitaxel from the male SD rat tail vein
- blood was collected from the jugular vein on occasion.
- the plasma obtained by centrifugation was diluted with an appropriate amount of water and extracted three times with tert-butyl methyl ether.
- the ether layer was recovered, dried, dissolved in 50 L of acetonitrile, and quantified by HPLC. The results are shown in Table 3.
- the micelle preparation of the present invention was maintained at a high plasma concentration as compared with the case where the paclitaxel single agent was administered.
- the Pakuryu xelel single agent In the area under the blood concentration one-hour curve (A ⁇ C), the Pakuryu xelel single agent: The micelle preparation of the present invention had a ratio of 1: about 1550.
- Test Example 3 Mice Toxicity Test for Stretch Reflex (Peripheral Neuropathy) Female mice with CDF 1 mice were administered micelle preparations 10 or ParkinuXel alone for 5 consecutive days from the mouse tail vein. We observed the stretch reflex of the mouse hind limb, which is an indicator of peripheral neuropathy.
- the micelle preparation of the present invention makes it possible to incorporate a drug having a required drug amount, in particular, paclitaxel, into a micelle without binding to a polymer.
- a drug having a required drug amount in particular, paclitaxel
- it should maintain a higher blood concentration than that of the drug alone have an effect that exceeds the efficacy of the drug alone, and reduce the toxicity observed with the drug alone.
- micelle preparation An anticancer agent containing the product as an active ingredient is also provided.
- a block copolymer suitable for forming a micelle preparation having the above effects is also provided.
- the block copolymer By using the block copolymer, it has also become possible to increase the solubility of the poorly water-soluble anticancer agent in water.
- the aqueous solution of the micelle preparation of the present invention when allowed to stand at room temperature, the release of the drug from the micelle preparation does not occur if the micelles are associated for at least several hours. According to the invention, it has also become possible to provide a micelle preparation containing a poorly water-soluble anticancer agent that is stably maintained in an aqueous medium.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polyamides (AREA)
- Peptides Or Proteins (AREA)
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL04721673T PL1604687T3 (pl) | 2003-03-20 | 2004-03-18 | Preparat micelarny zawierający słabo rozpuszczalny w wodzie lek przeciwnowotworowy oraz nowy kopolimer blokowy |
CN2004800073295A CN1761485B (zh) | 2003-03-20 | 2004-03-18 | 含略微水溶性抗癌剂和新型嵌段共聚物的胶束制剂 |
US10/548,998 US20060099265A1 (en) | 2003-03-20 | 2004-03-18 | Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer |
DK04721673.4T DK1604687T3 (da) | 2003-03-20 | 2004-03-18 | Micellefremstilling indeholdende ringe vandopløseligt anticancermiddel og ny blokcopolymer |
EP04721673A EP1604687B1 (en) | 2003-03-20 | 2004-03-18 | Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer |
JP2005503740A JP4757633B2 (ja) | 2003-03-20 | 2004-03-18 | 難水溶性抗癌剤と新規ブロック共重合体を含むミセル調製物 |
CA2518964A CA2518964C (en) | 2003-03-20 | 2004-03-18 | Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer |
DE602004029449T DE602004029449D1 (de) | 2003-03-20 | 2004-03-18 | Micellen-zubereitung mit schwer wasserlöslichem anti-krebsmittel und neuem blockcopolymer |
AT04721673T ATE483476T1 (de) | 2003-03-20 | 2004-03-18 | Micellen-zubereitung mit schwer wasserlöslichem anti-krebsmittel und neuem blockcopolymer |
AU2004222439A AU2004222439B2 (en) | 2003-03-20 | 2004-03-18 | Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer |
US14/108,875 US20140142167A1 (en) | 2003-03-20 | 2013-12-17 | Micellar Preparation Containing Sparingly Water-Soluble Anticancer Agent And Novel Block Copolymer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003077607 | 2003-03-20 | ||
JP2003-077607 | 2003-03-20 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/548,998 A-371-Of-International US20060099265A1 (en) | 2003-03-20 | 2004-03-18 | Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer |
US14/108,875 Division US20140142167A1 (en) | 2003-03-20 | 2013-12-17 | Micellar Preparation Containing Sparingly Water-Soluble Anticancer Agent And Novel Block Copolymer |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004082718A1 true WO2004082718A1 (ja) | 2004-09-30 |
Family
ID=33027953
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/003647 WO2004082718A1 (ja) | 2003-03-20 | 2004-03-18 | 難水溶性抗癌剤と新規ブロック共重合体を含むミセル調製物 |
Country Status (14)
Country | Link |
---|---|
US (3) | US20060099265A1 (ja) |
EP (1) | EP1604687B1 (ja) |
JP (1) | JP4757633B2 (ja) |
KR (1) | KR101064901B1 (ja) |
CN (1) | CN1761485B (ja) |
AT (1) | ATE483476T1 (ja) |
AU (1) | AU2004222439B2 (ja) |
CA (1) | CA2518964C (ja) |
DE (1) | DE602004029449D1 (ja) |
DK (1) | DK1604687T3 (ja) |
ES (1) | ES2351338T3 (ja) |
PL (1) | PL1604687T3 (ja) |
RU (1) | RU2324701C2 (ja) |
WO (1) | WO2004082718A1 (ja) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006132430A1 (ja) * | 2005-06-09 | 2006-12-14 | Nanocarrier Co., Ltd. | 白金錯体のポリマー化配位化合物の製造方法 |
WO2007136134A1 (ja) * | 2006-05-23 | 2007-11-29 | Nanocarrier Co., Ltd. | 疎水性薬物内包ポリマーミセルの製造方法 |
WO2009142328A1 (ja) | 2008-05-23 | 2009-11-26 | ナノキャリア株式会社 | カンプトテシン高分子誘導体及びその用途 |
WO2009142326A1 (ja) | 2008-05-23 | 2009-11-26 | ナノキャリア株式会社 | ドセタキセル高分子誘導体、並びにその製造方法及びその用途 |
US7820759B2 (en) | 2003-03-20 | 2010-10-26 | Nippon Kayaku Kabushiki Kaisha | Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer |
US8188222B2 (en) | 2006-11-08 | 2012-05-29 | Nippon Kayaku Kabushiki Kaisha | High molecular weight derivative of nucleic acid antimetabolite |
US8323669B2 (en) | 2006-03-28 | 2012-12-04 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of taxane |
US8334364B2 (en) | 2006-11-06 | 2012-12-18 | Nipon Kayaku Kabushiki Kaisha | High-molecular weight derivative of nucleic acid antimetabolite |
WO2013035641A1 (ja) | 2011-09-11 | 2013-03-14 | 日本化薬株式会社 | ブロック共重合体の製造方法 |
US8703878B2 (en) | 2007-09-28 | 2014-04-22 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
US8808749B2 (en) | 2009-05-15 | 2014-08-19 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of bioactive substance having hydroxy group |
US8920788B2 (en) | 2008-03-18 | 2014-12-30 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of physiologically active substances |
US8940332B2 (en) | 2006-05-18 | 2015-01-27 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of podophyllotoxins |
US9018323B2 (en) | 2010-11-17 | 2015-04-28 | Nippon Kayaku Kabushiki Kaisha | Polymer derivative of cytidine metabolic antagonist |
US9149540B2 (en) | 2008-05-08 | 2015-10-06 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of folic acid or folic acid derivative |
US10869937B2 (en) | 2016-07-30 | 2020-12-22 | Nippon Kayaku Kabushiki Kaisha | Polymer derivatives, and novel polymer derivative imaging probe using same |
US10945997B2 (en) | 2016-01-08 | 2021-03-16 | Nippon Kayaku Kabushiki Kaisha | Polymer derivative of macrolide immunosuppressant |
US10973762B2 (en) | 2016-08-02 | 2021-04-13 | Nippon Kayaku Kabushiki Kaisha | Active-targeting-type polymer derivative, composition containing said polymer derivative, and uses of said polymer derivative and said composition |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1792927T3 (pl) * | 2004-09-22 | 2013-09-30 | Nippon Kayaku Kk | Nowy kopolimer blokowy, preparat micelarny i lek przeciwnowotworowy zawierający ten preparat micelarny jako składnik czynny |
JP5548364B2 (ja) * | 2006-10-03 | 2014-07-16 | 日本化薬株式会社 | レゾルシノール誘導体の高分子結合体 |
MD3972C2 (ro) * | 2009-03-11 | 2010-07-31 | Ион МЕРЕУЦЭ | Remediu şi metodă de tratament al stărilor precanceroase |
DK2474306T3 (en) * | 2009-08-31 | 2017-02-06 | Nanocarrier Co Ltd | PARTICLE COMPOSITION AND PHARMACEUTICAL COMPOSITION CONTAINING SAME |
WO2022008527A1 (en) | 2020-07-06 | 2022-01-13 | Rheinisch-Westfälische Technische Hochschule (Rwth) Aachen | Polymeric micelles comprising glucuronide-prodrugs |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06206815A (ja) * | 1992-10-26 | 1994-07-26 | Nippon Kayaku Co Ltd | ブロック共重合体−抗癌剤複合体医薬製剤 |
JPH06206830A (ja) * | 1992-10-27 | 1994-07-26 | Nippon Kayaku Co Ltd | ブロック共重合体−薬剤複合体及び高分子ブロック共重合体 |
JPH06206832A (ja) * | 1992-10-27 | 1994-07-26 | Nippon Kayaku Co Ltd | 高分子担体 |
JPH08310970A (ja) * | 1995-08-21 | 1996-11-26 | Res Dev Corp Of Japan | 水溶性高分子化医薬製剤 |
JP2001226294A (ja) * | 2000-02-09 | 2001-08-21 | Nano Career Kk | 薬物が封入されたポリマーミセルの製造方法および該ポリマーミセル組成物 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1467587A (en) * | 1974-07-11 | 1977-03-16 | Nestle Sa | Preparation of an asparagine or a glutamine |
GB8500209D0 (en) * | 1985-01-04 | 1985-02-13 | Ceskoslovenska Akademie Ved | Synthetic polymeric drugs |
CH667874A5 (fr) * | 1985-12-19 | 1988-11-15 | Battelle Memorial Institute | Polypeptide synthetique biodegradable et son utilisation pour la preparation de medicaments. |
US4742113A (en) | 1987-02-20 | 1988-05-03 | Lord Corporation | Structural adhesive compositions |
US5182203A (en) * | 1989-03-29 | 1993-01-26 | E. I. Du Pont De Nemours And Company | Bifunctional compounds useful in catalyzed reporter deposition |
JP2517760B2 (ja) * | 1989-05-11 | 1996-07-24 | 新技術事業団 | 水溶性高分子化医薬製剤 |
US5543390A (en) * | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
KR940003548U (ko) * | 1992-08-14 | 1994-02-21 | 김형술 | 세탁물 건조기 |
US5985548A (en) * | 1993-02-04 | 1999-11-16 | E. I. Du Pont De Nemours And Company | Amplification of assay reporters by nucleic acid replication |
DE4307114A1 (de) * | 1993-03-06 | 1994-09-08 | Basf Ag | Verfahren zur Herstellung von Umsetzungsprodukten aus Polyasparaginsäureamid und Aminosäuren und ihre Verwendung |
US5552517A (en) * | 1995-03-03 | 1996-09-03 | Monsanto Company | Production of polysuccinimide in an organic medium |
WO1997033552A1 (en) * | 1996-03-12 | 1997-09-18 | Pg-Txl Company, L.P. | Water soluble paclitaxel prodrugs |
GB9625895D0 (en) * | 1996-12-13 | 1997-01-29 | Riley Patrick A | Novel compound useful as therapeutic agents and assay reagents |
EP0879604B1 (de) * | 1997-05-09 | 2003-04-09 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Konjugat, umfassend einen Folsäureantagonisten und einen Träger |
EP1037649B1 (en) * | 1997-12-17 | 2009-09-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
US6824766B2 (en) * | 1998-04-17 | 2004-11-30 | Enzon, Inc. | Biodegradable high molecular weight polymeric linkers and their conjugates |
JPH11335267A (ja) * | 1998-05-27 | 1999-12-07 | Nano Career Kk | 水難溶性薬物を含有するポリマーミセル系 |
IN191203B (ja) * | 1999-02-17 | 2003-10-04 | Amarnath Prof Maitra | |
US20030054977A1 (en) * | 1999-10-12 | 2003-03-20 | Cell Therapeutics, Inc. | Manufacture of polyglutamate-therapeutic agent conjugates |
WO2002065986A2 (en) * | 2001-02-16 | 2002-08-29 | Cellgate, Inc. | Transporters comprising spaced arginine moieties |
CA2476182A1 (en) * | 2002-03-01 | 2003-09-12 | The Administrators Of The Tulane Educational Fund | Conjugates of therapeutic or cytotoxic agents and biologically active peptides |
CN100490817C (zh) * | 2002-03-26 | 2009-05-27 | 万有制药株式会社 | 抗肿瘤吲哚并吡咯并咔唑衍生物和其它抗肿瘤药物联合用药 |
JP2004010479A (ja) * | 2002-06-03 | 2004-01-15 | Japan Science & Technology Corp | ブロック共重合体とアンスラサイクリン系抗癌剤を含む新規固型製剤及びその製造法 |
US7169892B2 (en) * | 2003-01-10 | 2007-01-30 | Astellas Pharma Inc. | Lipid-peptide-polymer conjugates for long blood circulation and tumor specific drug delivery systems |
CN1761485B (zh) | 2003-03-20 | 2010-04-28 | 日本化药株式会社 | 含略微水溶性抗癌剂和新型嵌段共聚物的胶束制剂 |
EP1594482A1 (en) * | 2003-03-26 | 2005-11-16 | LTT Bio-Pharma Co., Ltd. | Intravenous nanoparticles for targeting drug delivery and sustained drug release |
EP1680073B1 (en) * | 2003-10-21 | 2013-01-02 | IGF Oncology, LLC | Compounds and method for treating cancer |
FR2862536B1 (fr) * | 2003-11-21 | 2007-11-23 | Flamel Tech Sa | Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques |
US7176185B2 (en) * | 2003-11-25 | 2007-02-13 | Tsrl, Inc. | Short peptide carrier system for cellular delivery of agent |
EP2497785B1 (en) * | 2004-01-07 | 2018-09-12 | Seikagaku Corporation | Hyaluronic acid derivative and drug containing the same |
PL1792927T3 (pl) * | 2004-09-22 | 2013-09-30 | Nippon Kayaku Kk | Nowy kopolimer blokowy, preparat micelarny i lek przeciwnowotworowy zawierający ten preparat micelarny jako składnik czynny |
US8399464B2 (en) * | 2005-03-09 | 2013-03-19 | Nippon Kayaku Kabushiki Kaisha | HSP90 inhibitor |
WO2006095668A1 (ja) * | 2005-03-09 | 2006-09-14 | Toray Industries, Inc. | 微粒子および医薬品組成物 |
RU2404980C2 (ru) * | 2005-05-11 | 2010-11-27 | Ниппон Каяку Кабусики Кайся | Полимерное производное антиметаболита цитидина |
US20080280937A1 (en) * | 2005-08-19 | 2008-11-13 | Christopher Paul Leamon | Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives |
WO2007111211A1 (ja) * | 2006-03-28 | 2007-10-04 | Nippon Kayaku Kabushiki Kaisha | タキサン類の高分子結合体 |
JP5503872B2 (ja) * | 2006-11-06 | 2014-05-28 | 日本化薬株式会社 | 核酸系代謝拮抗剤の高分子誘導体 |
EP2090607B1 (en) * | 2006-11-08 | 2015-05-20 | Nippon Kayaku Kabushiki Kaisha | Polymeric derivative of nucleic acid metabolic antagonist |
USRE46190E1 (en) * | 2007-09-28 | 2016-11-01 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
CN101977631A (zh) * | 2008-03-18 | 2011-02-16 | 日本化药株式会社 | 生理活性物质的高分子量偶联物 |
JP5366940B2 (ja) * | 2008-05-08 | 2013-12-11 | 日本化薬株式会社 | 葉酸若しくは葉酸誘導体の高分子結合体 |
JP5544357B2 (ja) * | 2009-05-15 | 2014-07-09 | 日本化薬株式会社 | 水酸基を有する生理活性物質の高分子結合体 |
-
2004
- 2004-03-18 CN CN2004800073295A patent/CN1761485B/zh not_active Expired - Fee Related
- 2004-03-18 US US10/548,998 patent/US20060099265A1/en not_active Abandoned
- 2004-03-18 ES ES04721673T patent/ES2351338T3/es not_active Expired - Lifetime
- 2004-03-18 DK DK04721673.4T patent/DK1604687T3/da active
- 2004-03-18 WO PCT/JP2004/003647 patent/WO2004082718A1/ja active Application Filing
- 2004-03-18 JP JP2005503740A patent/JP4757633B2/ja not_active Expired - Fee Related
- 2004-03-18 EP EP04721673A patent/EP1604687B1/en not_active Expired - Lifetime
- 2004-03-18 KR KR1020057017245A patent/KR101064901B1/ko active IP Right Grant
- 2004-03-18 RU RU2005132309/04A patent/RU2324701C2/ru not_active IP Right Cessation
- 2004-03-18 AT AT04721673T patent/ATE483476T1/de active
- 2004-03-18 CA CA2518964A patent/CA2518964C/en not_active Expired - Fee Related
- 2004-03-18 AU AU2004222439A patent/AU2004222439B2/en not_active Ceased
- 2004-03-18 PL PL04721673T patent/PL1604687T3/pl unknown
- 2004-03-18 DE DE602004029449T patent/DE602004029449D1/de not_active Expired - Lifetime
-
2009
- 2009-01-30 US US12/322,322 patent/US7820759B2/en not_active Expired - Fee Related
-
2013
- 2013-12-17 US US14/108,875 patent/US20140142167A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06206815A (ja) * | 1992-10-26 | 1994-07-26 | Nippon Kayaku Co Ltd | ブロック共重合体−抗癌剤複合体医薬製剤 |
JPH06206830A (ja) * | 1992-10-27 | 1994-07-26 | Nippon Kayaku Co Ltd | ブロック共重合体−薬剤複合体及び高分子ブロック共重合体 |
JPH06206832A (ja) * | 1992-10-27 | 1994-07-26 | Nippon Kayaku Co Ltd | 高分子担体 |
JPH08310970A (ja) * | 1995-08-21 | 1996-11-26 | Res Dev Corp Of Japan | 水溶性高分子化医薬製剤 |
JP2001226294A (ja) * | 2000-02-09 | 2001-08-21 | Nano Career Kk | 薬物が封入されたポリマーミセルの製造方法および該ポリマーミセル組成物 |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7820759B2 (en) | 2003-03-20 | 2010-10-26 | Nippon Kayaku Kabushiki Kaisha | Micellar preparation containing sparingly water-soluble anticancer agent and novel block copolymer |
JP5201572B2 (ja) * | 2005-06-09 | 2013-06-05 | ナノキャリア株式会社 | 白金錯体のポリマー化配位化合物の製造方法 |
WO2006132430A1 (ja) * | 2005-06-09 | 2006-12-14 | Nanocarrier Co., Ltd. | 白金錯体のポリマー化配位化合物の製造方法 |
US7781607B2 (en) | 2005-06-09 | 2010-08-24 | Nanocarrier Co., Ltd. | Method for producing polymerized coordination compounds of platinum complex |
US8323669B2 (en) | 2006-03-28 | 2012-12-04 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of taxane |
US8940332B2 (en) | 2006-05-18 | 2015-01-27 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of podophyllotoxins |
WO2007136134A1 (ja) * | 2006-05-23 | 2007-11-29 | Nanocarrier Co., Ltd. | 疎水性薬物内包ポリマーミセルの製造方法 |
JPWO2007136134A1 (ja) * | 2006-05-23 | 2009-10-01 | ナノキャリア株式会社 | 疎水性薬物内包ポリマーミセルの製造方法 |
US8334364B2 (en) | 2006-11-06 | 2012-12-18 | Nipon Kayaku Kabushiki Kaisha | High-molecular weight derivative of nucleic acid antimetabolite |
US8188222B2 (en) | 2006-11-08 | 2012-05-29 | Nippon Kayaku Kabushiki Kaisha | High molecular weight derivative of nucleic acid antimetabolite |
US8703878B2 (en) | 2007-09-28 | 2014-04-22 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
USRE46190E1 (en) | 2007-09-28 | 2016-11-01 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of steroids |
US8920788B2 (en) | 2008-03-18 | 2014-12-30 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight conjugate of physiologically active substances |
US9149540B2 (en) | 2008-05-08 | 2015-10-06 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of folic acid or folic acid derivative |
WO2009142328A1 (ja) | 2008-05-23 | 2009-11-26 | ナノキャリア株式会社 | カンプトテシン高分子誘導体及びその用途 |
WO2009142326A1 (ja) | 2008-05-23 | 2009-11-26 | ナノキャリア株式会社 | ドセタキセル高分子誘導体、並びにその製造方法及びその用途 |
US8808749B2 (en) | 2009-05-15 | 2014-08-19 | Nippon Kayaku Kabushiki Kaisha | Polymer conjugate of bioactive substance having hydroxy group |
US9018323B2 (en) | 2010-11-17 | 2015-04-28 | Nippon Kayaku Kabushiki Kaisha | Polymer derivative of cytidine metabolic antagonist |
WO2013035641A1 (ja) | 2011-09-11 | 2013-03-14 | 日本化薬株式会社 | ブロック共重合体の製造方法 |
JPWO2013035641A1 (ja) * | 2011-09-11 | 2015-03-23 | 日本化薬株式会社 | ブロック共重合体の製造方法 |
US9346923B2 (en) | 2011-09-11 | 2016-05-24 | Nippon Kayaku Kabushiki Kaisha | Method for manufacturing block copolymer |
US10945997B2 (en) | 2016-01-08 | 2021-03-16 | Nippon Kayaku Kabushiki Kaisha | Polymer derivative of macrolide immunosuppressant |
US10869937B2 (en) | 2016-07-30 | 2020-12-22 | Nippon Kayaku Kabushiki Kaisha | Polymer derivatives, and novel polymer derivative imaging probe using same |
US10973762B2 (en) | 2016-08-02 | 2021-04-13 | Nippon Kayaku Kabushiki Kaisha | Active-targeting-type polymer derivative, composition containing said polymer derivative, and uses of said polymer derivative and said composition |
Also Published As
Publication number | Publication date |
---|---|
AU2004222439A1 (en) | 2004-09-30 |
US20140142167A1 (en) | 2014-05-22 |
KR101064901B1 (ko) | 2011-09-16 |
PL1604687T3 (pl) | 2011-04-29 |
RU2005132309A (ru) | 2006-04-10 |
EP1604687A1 (en) | 2005-12-14 |
EP1604687A4 (en) | 2009-03-18 |
DK1604687T3 (da) | 2010-11-15 |
ES2351338T3 (es) | 2011-02-03 |
CN1761485A (zh) | 2006-04-19 |
JPWO2004082718A1 (ja) | 2006-06-22 |
DE602004029449D1 (de) | 2010-11-18 |
RU2324701C2 (ru) | 2008-05-20 |
EP1604687B1 (en) | 2010-10-06 |
CA2518964A1 (en) | 2004-09-30 |
KR20050107800A (ko) | 2005-11-15 |
JP4757633B2 (ja) | 2011-08-24 |
US20060099265A1 (en) | 2006-05-11 |
AU2004222439B2 (en) | 2008-08-21 |
CN1761485B (zh) | 2010-04-28 |
US7820759B2 (en) | 2010-10-26 |
CA2518964C (en) | 2011-09-13 |
US20090156742A1 (en) | 2009-06-18 |
ATE483476T1 (de) | 2010-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004082718A1 (ja) | 難水溶性抗癌剤と新規ブロック共重合体を含むミセル調製物 | |
JP5369137B2 (ja) | 新規ブロック共重合体、ミセル調製物及びそれを有効成分とする抗癌剤 | |
EP3313857B1 (en) | Polymer-cyclodextrin-lipid conjugates | |
US6322805B1 (en) | Biodegradable polymeric micelle-type drug composition and method for the preparation thereof | |
EP2131814A2 (en) | Polymeric micelles for combination drug delivery | |
JP2015034172A (ja) | タキサン含有両親媒性ブロック共重合体ミセル組成物及びその製造方法 | |
JPWO2004039869A1 (ja) | カンプトテシン類の高分子誘導体 | |
WO2008056654A1 (en) | Polymeric derivative of nucleic acid metabolic antagonist | |
EP4245792A1 (en) | Copolymer containing poly(ethylene glycol) and poly(l-amino acid derivative), microparticles thereof, and use therefor in pharmaceutical composition | |
CN112105390A (zh) | 用于提高物理稳定性和增强抗肿瘤功效的胶束中低聚乳酸缀合物的立体复合物 | |
WO2023145539A1 (ja) | ポリ(疎水化システイン)セグメントをブロックとして含む共重合体及びその治療用途 | |
AU2022256993A1 (en) | Docetaxel-aconitic anhydride conjugate exhibiting anti-tumor activity without in vivo toxicity | |
CN117298288A (zh) | 多糖抗肿瘤小分子药物共聚物及其转铁蛋白修饰自组装纳米粒和制法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005503740 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004721673 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004222439 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2518964 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057017245 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048073295 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2004222439 Country of ref document: AU Date of ref document: 20040318 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004222439 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005132309 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2006099265 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10548998 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057017245 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004721673 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10548998 Country of ref document: US |